Yamamoto T - Search Results

1

Cumulative probability of PSA increase above 4.0 NG/ML in population-based screening for prostate cancer.

Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Among authors: yamamoto t. Int J Cancer. 2004 Apr 10;109(3):455-60. doi: 10.1002/ijc.11711. Int J Cancer. 2004. PMID: 14961587

2

Rapidly progressive malignant epithelioid angiomyolipoma of the kidney.

Yamamoto T, Ito K, Suzuki K, Yamanaka H, Ebihara K, Sasaki A. Yamamoto T, et al. J Urol. 2002 Jul;168(1):190-1. J Urol. 2002. PMID: 12050523 No abstract available.

3

Usefulness of prostate-specific antigen velocity in screening for prostate cancer.

Ito K, Yamamoto T, Ohi M, Kubota Y, Fukabori Y, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Among authors: yamamoto t. Int J Urol. 2002 Jun;9(6):316-21. doi: 10.1046/j.1442-2042.2002.00466.x. Int J Urol. 2002. PMID: 12110095 Free article.

4

Genistein, a soy isoflavone, induces glutathione peroxidase in the human prostate cancer cell lines LNCaP and PC-3.

Suzuki K, Koike H, Matsui H, Ono Y, Hasumi M, Nakazato H, Okugi H, Sekine Y, Oki K, Ito K, Yamamoto T, Fukabori Y, Kurokawa K, Yamanaka H. Suzuki K, et al. Among authors: yamamoto t. Int J Cancer. 2002 Jun 20;99(6):846-52. doi: 10.1002/ijc.10428. Int J Cancer. 2002. PMID: 12115487

5

The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL.

Ito K, Ohi M, Yamamoto T, Miyamoto S, Kurokawa K, Fukabori Y, Suzuki K, Yamanaka H. Ito K, et al. Among authors: yamamoto t. Cancer. 2002 Nov 15;95(10):2112-9. doi: 10.1002/cncr.10941. Cancer. 2002. PMID: 12412164 Free article.

6

Salvage external beam radiotherapy for local recurrence without systemic progression or prostate specific antigen recurrence of prostate cancer after initial hormonal therapy: is it possible to identify patients likely to have good treatment outcomes?

Kurokawa K, Ito K, Suzuki K, Ono Y, Yamamoto T, Akimoto T, Yamanaka H. Kurokawa K, et al. Among authors: yamamoto t. Jpn J Clin Oncol. 2002 Nov;32(11):466-71. doi: 10.1093/jjco/hyf096. Jpn J Clin Oncol. 2002. PMID: 12499419

7

Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1 to 10.0 ng/mL.

Ito K, Yamamoto T, Ohi M, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Among authors: yamamoto t. Urology. 2003 Apr;61(4):760-4. doi: 10.1016/s0090-4295(02)02427-5. Urology. 2003. PMID: 12670561

8

Natural history of PSA increase with and without prostate cancer.

Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Among authors: yamamoto t. Urology. 2003 Jul;62(1):64-9. doi: 10.1016/s0090-4295(03)00135-3. Urology. 2003. PMID: 12837424

9

Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.

Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Ito K, et al. Among authors: yamamoto t. Prostate. 2003 Sep 15;57(1):8-13. doi: 10.1002/pros.10268. Prostate. 2003. PMID: 12886518

10

The combination of multi-voxel MR spectroscopy with MR imaging improve the diagnostic accuracy for localization of prostate cancer.

Hasumi M, Suzuki K, Taketomi A, Matsui H, Yamamoto T, Ito K, Kurokawa K, Aoki J, Endo K, Yamanaka H. Hasumi M, et al. Among authors: yamamoto t. Anticancer Res. 2003 Sep-Oct;23(5b):4223-7. Anticancer Res. 2003. PMID: 14666629

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

17,371 results

Search Page

Filters